Mar 14, 2023 / 05:20PM GMT
Alex Xu - Oppenheimer & Co. Inc. - Analyst
Great. Hello, everyone. Thank you for tuning in for the 33rd Annual Oppenheimer Healthcare Conference. My name is Alex. I work with Mark Breidenbach. And I'm here today with Kevin Xie the Chief Financial Officer of Gracell Bio.
Just a quick overview, Gracell, they're a biotechnology company working on the creation of both autologous and allogeneic cellular therapies. Some of you may have heard of their fast hard technology. And I think Kevin is here to talk a little bit more about what they're working on today.
So if it's okay with you, I'd like to hand it off to you, Kevin.
Kevin Xie - Gracell Biotechnologies Inc. - CFO
Thank you, Alex, for that intro and the OpCo for inviting us to present our clinical program today.
So -- let me just scroll down this forward-looking statement disclaimer. I think you're all familiar with this.
I guess, I'll start from here. So as Alex has kindly made introduction, Gracell is a global clinical stage biotech company. Our focus is on cell
Gracell Biotechnologies Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 14, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers